Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Buys 15,009 Shares

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. acquired 15,009 shares of Anixa Biosciences stock in a transaction on Tuesday, April 9th. The stock was purchased at an average cost of $3.28 per share, for a total transaction of $49,229.52. Following the purchase, the director now owns 838,037 shares in the company, valued at $2,748,761.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Anixa Biosciences Stock Performance

NASDAQ:ANIX traded up $0.10 during trading hours on Wednesday, reaching $3.35. The stock had a trading volume of 24,915 shares, compared to its average volume of 146,858. Anixa Biosciences, Inc. has a 52 week low of $2.75 and a 52 week high of $6.45. The company has a 50 day moving average price of $3.68 and a two-hundred day moving average price of $3.64.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). As a group, equities analysts anticipate that Anixa Biosciences, Inc. will post -0.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Anixa Biosciences in a research note on Thursday, March 21st.

Hedge Funds Weigh In On Anixa Biosciences

Large investors have recently modified their holdings of the stock. Mission Wealth Management LP bought a new position in shares of Anixa Biosciences during the 3rd quarter valued at approximately $1,639,000. Dakota Wealth Management bought a new position in shares of Anixa Biosciences during the 3rd quarter valued at approximately $49,000. JPMorgan Chase & Co. grew its position in Anixa Biosciences by 383.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 27,289 shares of the company’s stock valued at $87,000 after acquiring an additional 21,639 shares during the last quarter. CI Private Wealth LLC bought a new position in Anixa Biosciences in the 4th quarter valued at $85,000. Finally, B. Riley Wealth Advisors Inc. bought a new position in Anixa Biosciences in the 3rd quarter valued at $80,000. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.